You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2025

CLINICAL TRIALS PROFILE FOR ILEVRO


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for ILEVRO

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT02752646 ↗ Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5% Completed Alcon Research N/A 2016-04-01 This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs ketorolac 0.5% among patients undergoing cataract surgery.
NCT02515045 ↗ Dropless vs. Standard Drops Contralateral Eye Study Completed Science in Vision Phase 4 2015-01-01 To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.
NCT02515045 ↗ Dropless vs. Standard Drops Contralateral Eye Study Completed Carolina Eyecare Physicians, LLC Phase 4 2015-01-01 To compare the use of an injectable compound containing an antibiotic and an anti-inflammatory at time of cataract surgery to standard of care that is the use 3 different topical medications to prevent inflammation and infection after routine cataract surgery.
NCT01847638 ↗ Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery Completed Bausch & Lomb Incorporated N/A 2013-04-01 To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT01847638 ↗ Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery Completed Melissa Toyos N/A 2013-04-01 To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
NCT01847638 ↗ Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery Completed Melissa Toyos, MD N/A 2013-04-01 To investigate inflammation, visual acuity and macular thickness after treatment with Prolensa vs Ilevro after cataract surgery.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 6 of 6 entries

Clinical Trial Conditions for ILEVRO

Condition Name

3111000.511.522.53CataractTreatment of Ocular Inflammation Associated With Cataract SurgeryGrade of Post-Operative Cystoid Macular EdemaInflammation[disabled in preview]
Condition Name for ILEVRO
Intervention Trials
Cataract 3
Treatment of Ocular Inflammation Associated With Cataract Surgery 1
Grade of Post-Operative Cystoid Macular Edema 1
Inflammation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

4311000.511.522.533.54CataractInflammationMacular EdemaEdema[disabled in preview]
Condition MeSH for ILEVRO
Intervention Trials
Cataract 4
Inflammation 3
Macular Edema 1
Edema 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ILEVRO

Trials by Country

+
Trials by Country for ILEVRO
Location Trials
United States 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for ILEVRO
Location Trials
Montana 1
Kentucky 1
California 1
South Carolina 1
New York 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ILEVRO

Clinical Trial Phase

60.0%40.0%000.511.522.53Phase 4N/A[disabled in preview]
Clinical Trial Phase for ILEVRO
Clinical Trial Phase Trials
Phase 4 3
N/A 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

80.0%20.0%000.511.522.533.54CompletedRecruiting[disabled in preview]
Clinical Trial Status for ILEVRO
Clinical Trial Phase Trials
Completed 4
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ILEVRO

Sponsor Name

trials0112233Bausch & Lomb IncorporatedMelissa ToyosMelissa Toyos, MD[disabled in preview]
Sponsor Name for ILEVRO
Sponsor Trials
Bausch & Lomb Incorporated 2
Melissa Toyos 1
Melissa Toyos, MD 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

75.0%25.0%00123456789OtherIndustry[disabled in preview]
Sponsor Type for ILEVRO
Sponsor Trials
Other 9
Industry 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Ilevro (Nepafenac Ophthalmic Suspension)

Clinical Trials Overview

Ilevro, also known as nepafenac ophthalmic suspension, has undergone extensive clinical trials to evaluate its efficacy and safety in treating postoperative pain and inflammation associated with cataract surgery.

Study Design and Patient Population

In two pivotal clinical studies, 3462 patients were randomized, with 1339 patients receiving Ilevro ophthalmic suspension. These studies involved patients undergoing cataract surgery by phacoemulsification and implantation of a posterior chamber intraocular lens. Patients were dosed with Ilevro once daily, starting one day prior to surgery and continuing for 14 days postoperatively[4].

Efficacy

The clinical trials demonstrated that Ilevro was highly effective in reducing postoperative pain and inflammation. The drug showed superior clinical efficacy compared to its vehicle in treating these conditions. By day 14 post-operation, Ilevro cleared inflammation in 65% and 68% of patients, significantly higher than the vehicle group (25% and 35%). Additionally, pain-free rates in the Ilevro group were 89% and 91%, compared to 40% and 50% in the vehicle group[4].

Safety and Adverse Events

The safety profile of Ilevro was favorable, with the most common adverse events being headache and increased intraocular pressure, both of which were mild to moderate in intensity. Headache was observed in 2.0% of patients treated with Ilevro, and intraocular pressure increases were seen in 1.1% of patients. These events typically resolved within 5 days following treatment initiation[1][4].

Market Analysis

Current Market Landscape

The ophthalmic drugs market, which includes Ilevro, is a significant segment within the pharmaceutical industry. In 2021, the global ophthalmic drugs market was valued at USD 67.1 billion and is projected to grow at a CAGR of 7.40% from 2022 to 2030[5].

Market Segments

  • Disease Insights: The retinal disorder segment dominated the market in 2021, driven by the rising prevalence of age-related macular degeneration and diabetic retinopathy. However, Ilevro is specifically used for postoperative pain and inflammation, positioning it within the broader anti-inflammatory segment[5].
  • Route of Administration: The topical route of administration, which includes eye drops like Ilevro, dominated the market due to its targeted delivery and ease of use[5].

Competitive Landscape

Ilevro competes with other anti-inflammatory ophthalmic drugs such as Lotemax, Zylet, and Durezol. The prescription drugs segment, which includes Ilevro, held the largest revenue share of 60.1% in 2021 and is expected to maintain its dominance throughout the forecast period[5].

Market Projections

Global Market Growth

The global ophthalmic drugs market is expected to reach USD 67.1 billion by 2030, driven by factors such as the rising prevalence of ophthalmic disorders, advancements in healthcare infrastructure, and increasing demand for eye care products[5].

Regional Growth

North America currently holds the largest market share, but the Asia Pacific region is expected to exhibit the fastest growth due to its large patient pool and improving healthcare infrastructure[5].

Promotional Activities

In 2019, Novartis, the manufacturer of Ilevro, engaged in various promotional activities, including sales rep detailing, physician education, and paid speaking engagements. These activities helped in reaching a significant number of physicians and maintaining a strong market presence[2].

Key Takeaways

  • Efficacy and Safety: Ilevro has demonstrated strong efficacy in reducing postoperative pain and inflammation with a favorable safety profile.
  • Market Growth: The ophthalmic drugs market, including Ilevro, is projected to grow significantly, driven by increasing demand and advancements in healthcare.
  • Competitive Landscape: Ilevro competes within a crowded market but maintains a strong position due to its targeted use and prescription dominance.
  • Regional Expansion: The Asia Pacific region is expected to drive future growth due to its large patient pool and improving healthcare infrastructure.

FAQs

What is Ilevro used for?

Ilevro (nepafenac ophthalmic suspension) is used for the prevention and treatment of postoperative pain and inflammation associated with cataract surgery[4].

What were the common adverse events observed in clinical trials of Ilevro?

The most common adverse events were headache and increased intraocular pressure, both of which were mild to moderate in intensity[1][4].

How does Ilevro compare to its competitors in the market?

Ilevro competes with other anti-inflammatory ophthalmic drugs but maintains a strong position due to its targeted use and prescription dominance within the ophthalmic drugs market[5].

What is the projected growth of the ophthalmic drugs market?

The global ophthalmic drugs market is expected to grow at a CAGR of 7.40% from 2022 to 2030, reaching USD 67.1 billion by 2030[5].

Which region is expected to drive the future growth of the ophthalmic drugs market?

The Asia Pacific region is expected to exhibit the fastest growth due to its large patient pool and improving healthcare infrastructure[5].

Sources

  1. Novartis Pharma: Pr ILEVRO® - Ask Novartis Pharma.
  2. MDDetails: Ilevro 2019 U.S. PROMOTIONAL AUDIT REPORT.
  3. BioSpace: Europe Clinical Trials Market Size to Hit USD 43 Billion by 2034.
  4. Medsafe: Ilevro Eye Drops.
  5. BioSpace: Ophthalmic Drugs Market Demand and Growth Analysis with Forecast up to 2030.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.